Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Kibow PharmaPrivate | 1 asset: 1 Ph 3 | KT-301Phase 2/3 · Chronic Kidney Disease | None on record |
 Kinaset TherapeuticsPrivate | 1 asset: 1 Ph 2 | frevecitinibPhase 2 · Chronic Obstructive Pulmonary DiseasePartial signal | 30 Nov 2027frevecitinib · Phase 2 |
 Kind PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | AND017Phase 3 · Chronic Kidney DiseasePartial signal | 30 Oct 2026AND017 · Phase 3 |
King Pharmaceuticals, Inc.Private | 1 asset: 1 approved | Approved assets only | None on record |
 Kiora Pharmaceuticals, Inc.KPRX · Nasdaq | 1 asset: 1 Ph 2 | KIO-301Phase 2 · Retinitis Pigmentosa | Aug 2027KIO-301 · Phase 2 |
 Kiromic BioPharma Inc.KRBPQ · OTC Pink | 1 asset: 1 Ph 1 | KB-GDT-01Phase 1 · Non-Small Cell Lung Cancer | None on record |
 Kither BiotechPrivate | 1 asset: 1 Ph 2 | KIT2014Phase 1/2 · Chronic Obstructive Pulmonary Disease | 31 Mar 2027KIT2014 · Phase 1/2 |
 Kivu Bioscience Inc.Private | 1 asset: 1 Ph 1 | KIVU-107Phase 1 · Non-Small Cell Lung Cancer | 31 Mar 2028KIVU-107 · Phase 1 |
| 1 asset: 1 Ph 1 | KS101Phase 1 · Alzheimer's Disease | None on record | |
 Kumquat Biosciences Inc.Private | 1 asset: 1 Ph 1 | KQB368Phase 1 · Non-Small Cell Lung Cancer | Dec 2029KQB368 · Phase 1 |
 Kure Cells, Inc.Private | 1 asset: 1 Ph 1 | UF-KURE-BCMAPhase 1 · Multiple Myeloma | 30 Sep 2028UF-KURE-BCMA · Phase 1 |
 LAPIX TherapeuticsPrivate | 1 asset: 1 Ph 1 | LPX-TI641Phase 1 · Psoriatic Arthritis | None on record |
 LB PharmaceuticalsLBRX · Nasdaq | 1 asset: 1 Ph 3 | LB-102 (methylated amisulpride)Phase 3 · SchizophreniaReliable signal | None on record |
 LIB TherapeuticsPrivate | 1 asset: 1 Ph 3 | LerodalcibepPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 31 Jul 2028Lerodalcibep · Phase 3 |
 Lee's Pharmaceutical0950 · HKEX | 1 asset: 1 approved | Approved assets only | None on record |
 Lexeo TherapeuticsLXEO · Nasdaq | 1 asset: 1 Ph 2 | LX1001Phase 1/2 · Alzheimer's DiseaseWeak signal | Nov 2028LX1001 · Phase 1 |
Libella Gene TherapeuticsPrivate | 1 asset: 1 Ph 1 | AAV-hTERTPhase 1 · Alzheimer's DiseaseWeak signal | None on record |
 LigaChem Biosciences, Inc.141080 · KOSDAQ | 1 asset: 1 Ph 2 | LCB84Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2027LCB84 · Phase 1/2 |
| 1 asset: 1 Ph 1 | NI-1801Phase 1 · Non-Small Cell Lung Cancer | None on record | |
 Lighthouse PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | LHP588Phase 2 · Alzheimer's Disease | 31 Jan 2029LHP588 · Phase 2 |
 Lingyi Biotech Co., Ltd.Private | 1 asset: 1 Ph 1 | LY-N001Phase 1 · Parkinson's Disease | 7 Jul 2028LY-N001 · Phase 1 |
 Linnaeus Therapeutics, Inc.Private | 1 asset: 1 Ph 3 | LNS8801Phase 2/3 · Non-Small Cell Lung Cancer | Feb 2029LNS8801 · Phase 2/3 |
 Lipocine Inc.LPCN · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 Lisata TherapeuticsLSTA · Nasdaq | 1 asset: 1 Ph 2 | certepetidePhase 2 · Pancreatic Cancer | None on record |
 Lmito TherapeuticsPrivate | 1 asset: 1 Ph 1 | LMT503Phase 1 · Ulcerative Colitis | 1 Sep 2027LMT503 · Phase 1 |
 LobSor Pharmaceuticals ABPrivate | 1 asset: 1 Ph 1 | TrigelPhase 1 · Parkinson's DiseasePartial signal | None on record |
 Longeveron (NASDAQ: LGVN)LGVN · Nasdaq | 1 asset: 1 Ph 2 | LaromestrocelPhase 2 · Alzheimer's DiseasePartial signal | None on record |
| 1 asset: 1 Ph 1 | LBT-3627Phase 1 · Parkinson's Disease | Feb 2027LBT-3627 · Phase 1 | |
 Lupin LimitedLUPIN · NSE | 1 asset: 1 approved | Approved assets only | 4 Feb 2027Ranibizumab · Phase 3 |
 LyncBio TherapeuticsPrivate | 1 asset: 1 Ph 1 | LYNC-101Phase 1 · Ulcerative Colitis | 19 Mar 2027LYNC-101 · Phase 1 |
 MODAG GmbHPrivate | 1 asset: 1 Ph 1 | Anle138bPhase 1 · Parkinson's DiseasePartial signal | 15 Jan 2027Anle138b · Phase 1 |
 MTI Biotech Inc.Private | 1 asset: 1 Ph 2 | 2-hydroxybenzylamine acetatePhase 1/2 · Alzheimer's Disease | 30 Dec 20282-hydroxybenzylamine acetate · Phase 1/2 |
 Mabpro, a.s.Private | 1 asset: 1 Ph 1 | CA9hu-1Phase 1 · Non-Small Cell Lung Cancer | None on record |
 Mabwell Bioscience688062 · SSE STAR Market | 1 asset: 1 Ph 2 | 9MW1911Phase 2 · Chronic Obstructive Pulmonary DiseasePartial signal | Dec 20279MW1911 · Phase 2 |
Mage BiologicsPrivate | 1 asset: 1 Ph 2 | MB-001Phase 1/2 · Ulcerative ColitisPartial signal | Jul 2028MB-001 · Phase 1/2 |
 MapLight TherapeuticsMPLT · Nasdaq | 1 asset: 1 Ph 2 | ML-007C-MAPhase 2 · SchizophreniaPartial signal | Dec 2027ML-007C-MA · Phase 2 |
 Mapi PharmaPrivate | 1 asset: 1 Ph 2 | Cariprazine long-acting injection (Mapi Pharma)Phase 1/2 · Schizophrenia | 31 Dec 2026Cariprazine long-acting injection (Mapi Pharma) · Phase 1/2 |
 Marea TherapeuticsPrivate | 1 asset: 1 Ph 2 | MAR001Phase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | Nov 2027MAR001 · Phase 2 |
 Marengo Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | STAR0602Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2027STAR0602 · Phase 1/2 |
 Matinas BioPharmaMTNB · Nasdaq | 1 asset: 1 Ph 3 | MAT2203Phase 3 · Cryptococcal Meningitis | None on record |
 Maze TherapeuticsMAZE · Nasdaq | 1 asset: 1 Ph 2 | MZE829Phase 2 · Chronic Kidney Disease | None on record |
| 1 asset: 1 Ph 2 | NanoLithium NP03Phase 2 · Alzheimer's DiseasePartial signal | None on record | |
| 1 asset: 1 Ph 3 | PM012Phase 2/3 · Alzheimer's DiseasePartial signal | None on record | |
 Medivir ABMVIR · Nasdaq Stockholm | 1 asset: 1 Ph 2 | BirinapantPhase 2 · Ovarian Cancer | None on record |
 MeiraGTx LimitedPrivate | 1 asset: 1 Ph 2 | AAV-GAD gene therapyPhase 2 · Parkinson's DiseasePartial signal | Oct 2029AAV-GAD gene therapy · Phase 1/2 |
 Meitheal PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 Memgen, Inc.Private | 1 asset: 1 Ph 1 | MEM-288Phase 1 · Non-Small Cell Lung Cancer | Feb 2027MEM-288 · Phase 1 |
 MendusPrivate | 1 asset: 1 Ph 2 | DCP-001Phase 2 · Acute Myeloid LeukemiaWeak signal | None on record |
 Meridigen BiotechPrivate | 1 asset: 1 Ph 2 | UMC119-06Phase 2 · Chronic Obstructive Pulmonary DiseaseWeak signal | None on record |
| 1 asset: 1 Ph 2 | TML-6Phase 2 · Alzheimer's DiseasePartial signal | 30 Apr 2028TML-6 · Phase 2 | |
MeryxPrivate | 1 asset: 1 Ph 2 | MRX-2843Phase 1/2 · Acute Myeloid LeukemiaWeak signal | None on record |
 Merz PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | IncobotulinumtoxinA (Xeomin, PD sialorrhea)Phase 3 · Parkinson's DiseasePartial signal | None on record |
 MiNK Therapeutics, Inc.INKT · Nasdaq | 1 asset: 1 Ph 2 | agenT-797Phase 2 · Gastric CancerWeak signal | Jun 2027agenT-797 · Phase 2 |
 MicrobioticaPrivate | 1 asset: 1 Ph 1 | MB310Phase 1 · Ulcerative ColitisPartial signal | None on record |
 MindRank AIPrivate | 1 asset: 1 Ph 3 | MDR-001Phase 3 · Obesity | Jun 2027MDR-001 · Phase 3 |
 Mineralys TherapeuticsMLYS · Nasdaq | 1 asset: 1 Ph 3 | LorundrostatPhase 3 · HypertensionReliable signal | None on record |
 Minerva NeurosciencesNERV · Nasdaq | 1 asset: 1 Ph 3 | RoluperidonePhase 3 · SchizophreniaPartial signal | Dec 2027Roluperidone · Phase 3 |
 Mission TherapeuticsPrivate | 1 asset: 1 Ph 1 | MTX325Phase 1 · Parkinson's Disease | 30 Jun 2027MTX325 · Phase 1 |
 Moleac Pte LtdPrivate | 1 asset: 1 Ph 3 | MLC901Phase 3 · Alzheimer's Disease | Feb 2029MLC901 · Phase 3 |
 MoleculinMBRX · Nasdaq | 1 asset: 1 Ph 3 | AnnamycinPhase 2/3 · Acute Myeloid Leukemia | Aug 2029Annamycin · Phase 2/3 |
 MoonLake ImmunotherapeuticsMLTX · Nasdaq | 1 asset: 1 Ph 3 | sonelokimabPhase 3 · Psoriatic ArthritisReliable signal | 15 Jan 2027sonelokimab · Phase 3 |
 Mthera Pharma Co., Ltd.Private | 1 asset: 1 Ph 2 | MT101-5Phase 2 · Parkinson's DiseasePartial signal | None on record |
 Multitude Therapeutics Inc.Private | 1 asset: 1 Ph 3 | AMT-116Phase 2/3 · Non-Small Cell Lung Cancer | 30 Dec 2026AMT-116 · Phase 1 |
 NEUROBiOGENPrivate | 1 asset: 1 Ph 2 | KDS2010Phase 2 · Alzheimer's Disease | 31 Jan 2027KDS2010 · Phase 2 |
 NGM BiopharmaceuticalsPrivate | 1 asset: 1 Ph 2 | NGM707Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record |
 NKGen BiotechNKGN · OTC | 1 asset: 1 Ph 2 | SNK01Phase 1/2 · Alzheimer's DiseaseWeak signal | Mar 2028SNK01 · Phase 1/2 |
 NRx PharmaceuticalsNRXP · Nasdaq | 1 asset: 1 Ph 3 | NRX-101Phase 3 · Bipolar Depression | None on record |
 NSC-TherapeuticsPrivate | 1 asset: 1 Ph 2 | NSC001Phase 1/2 · Alzheimer's Disease | None on record |
 Nammi Therapeutics IncPrivate | 1 asset: 1 Ph 1 | QXL138AMPhase 1 · Multiple Myeloma | 31 Dec 2027QXL138AM · Phase 1 |
 Nanjing Immunophage BiotechPrivate | 1 asset: 1 Ph 2 | IPG11406Phase 2 · Ulcerative ColitisPartial signal | 1 Dec 2028IPG11406 · Phase 2 |
 Nanjing RegeneCore BiotechPrivate | 1 asset: 1 Ph 2 | RC1416Phase 2 · Chronic Obstructive Pulmonary Disease | 25 Oct 2027RC1416 · Phase 2 |
 NanobiotixNBTX · Nasdaq | 1 asset: 1 Ph 3 | NBTXR3Phase 3 · Non-Small Cell Lung Cancer | 30 Apr 2027NBTXR3 · Phase 1 |
| 1 asset: 1 Ph 3 | NNG-DEPOPhase 3 · Chronic Kidney DiseasePartial signal | None on record | |
 Napo PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | Dec 2026Crofelemer · Phase 2/3 |
 Nature Cell Co., Ltd.007390 · KOSDAQ | 1 asset: 1 Ph 2 | AstroStemPhase 2 · Alzheimer's DiseasePartial signal | None on record |
 NavigenPrivate | 1 asset: 1 Ph 1 | CPT31Phase 1 · HIVPartial signal | None on record |
| 1 asset: 1 Ph 1 | BBP-398Phase 1 · Non-Small Cell Lung CancerWeak signal | None on record | |
 NeoTX Therapeutics Ltd.Private | 1 asset: 1 Ph 3 | Naptumomab estafenatoxPhase 2/3 · Non-Small Cell Lung CancerWeak signal | 1 Mar 2027Naptumomab estafenatox · Phase 1 |
 Nerviano Medical SciencesPrivate | 1 asset: 1 Ph 1 | NMS-03597812Phase 1 · Acute Myeloid Leukemia | 15 Sep 2029NMS-03597812 · Phase 1 |
| 1 asset: 1 Ph 2 | atamparibPhase 1/2 · Non-Small Cell Lung Cancer | 31 Jul 2028atamparib · Phase 1/2 | |
 Nested Therapeutics, IncPrivate | 1 asset: 1 Ph 1 | NST-628Phase 1 · Non-Small Cell Lung Cancer | Nov 2028NST-628 · Phase 1 |
 Neurelis, Inc.Private | 1 asset: 1 approved | Approved assets only | None on record |
| 1 asset: 1 Ph 2 | TraneurocinPhase 2 · Alzheimer's DiseasePartial signal | None on record | |
 NeuroDerm Ltd.Private | 1 asset: 1 Ph 3 | ND0612Phase 3 · Parkinson's DiseasePartial signal | None on record |
 NeuroPro Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | NPT2042Phase 2 · EpilepsyPartial signal | None on record |
 NeuroTherapia, Inc.Private | 1 asset: 1 Ph 2 | NTRX-07Phase 2 · Alzheimer's DiseasePartial signal | None on record |
| 1 asset: 1 approved | Approved assets only | None on record | |
 NeurolixisPrivate | 1 asset: 1 Ph 2 | NLX-112Phase 2 · Parkinson's Disease | None on record |
 Neuron23Private | 1 asset: 1 Ph 2 | NEU-411Phase 2 · Parkinson's Disease | Dec 2027NEU-411 · Phase 2 |
 Neuronascent, Inc.Private | 1 asset: 1 Ph 1 | NNI-362Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 Neurosterix Pharma SàrlPrivate | 1 asset: 1 Ph 1 | NTX-253Phase 1 · Schizophrenia | None on record |
 NewAmsterdam PharmaNAMS · Nasdaq | 1 asset: 1 Ph 3 | ObicetrapibPhase 3 · Type 2 DiabetesPartial signal | Nov 2026Obicetrapib · Phase 3 |
 Newave Pharmaceutical IncPrivate | 1 asset: 1 Ph 1 | LP-118Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026LP-118 · Phase 1 |
 Newron Sweden ABPrivate | 1 asset: 1 Ph 1 | sNN0029 infusion solutionPhase 1 | None on record |
 NiKang Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | NKT5097Phase 1 · HR+/HER2- Metastatic Breast Cancer | 31 Jul 2027NKT5097 · Phase 1 |
 Nimbus Saturn, Inc.Private | 1 asset: 1 Ph 2 | NDI-101150Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
| 1 asset: 1 Ph 3 | WD-890Phase 3 · Psoriasis | 30 Nov 2026WD-890 · Phase 3 | |
 NodTheraPrivate | 1 asset: 1 Ph 2 | NT-0796Phase 2 · ObesityPartial signal | None on record |
 Normunity AccelCo, Inc.Private | 1 asset: 1 Ph 1 | NRM-823Phase 1 · Non-Small Cell Lung Cancer | 30 May 2027NRM-823 · Phase 1 |
 NorthSea Therapeutics B.V.Private | 1 asset: 1 Ph 2 | SEFA-1024Phase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).